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a  b  s  t  r  a  c  t
A  toxicological  evaluation  of  two novel  bitter  modifying  ﬂavour  compounds,  3-(1-((3,5-
dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-(3-hydroxybenzyl)imidazolidine-2,4-dione
(S6821,  CAS  1119831-25-2)  and 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-(3-
hydroxybenzyl)-5,5-dimethylimidazolidine-2,4-dione  (S7958,  CAS  1217341-48-4),  were  completed
for  the  purpose  of  assessing  their  safety  for use  in food and  beverage  applications.  S6821 undergoes
oxidative  metabolism  in  vitro,  and  in rat pharmacokinetic  studies  both  S6821  and  S7958 are  rapidly
converted  to the corresponding  O-sulfate  and  O-glucuronide  conjugates.  S6821  was  not  found  to
be  mutagenic  or clastogenic  in  vitro,  and  did  not  induce  micronuclei  in bone  marrow  polychromatic
erythrocytes  in  vivo.  S7958,  a close  structural  analog  of S6821,  was  also  found  to  be  non-mutagenic
in vitro.  In  short  term  and  subchronic  oral  toxicity  studies  in rats,  the  no-observed-adverse-effect-levelenetic toxicological evaluation (NOAEL)  for  both  S7958  and S6821  was  100  mg/kg  bw/day  (highest  dose  tested)  when  administered
as a food  ad-mix  for either  28  or 90  consecutive  days,  respectively.  Furthermore,  S6821  demonstrated
a  lack  of maternal  toxicity,  as  well  as adverse  effects  on  fetal  morphology  at the  highest  dose  tested,
providing  a NOAEL  of 1000  mg/kg  bw/day  for both  maternal  toxicity  and embryo/fetal  development
when  administered  orally  during  gestation  to  pregnant  rats.
© 2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CCAbbreviations: AUC, area under the curve; CL, plasma clearance; Cmax, peak
lasma concentration; CYP, cytochrome P450; FDA, Food and Drug Administra-
ion; FEMA, Flavour and Extract Manufacturers Association of the United States;
LP, Good Laboratory Practices; GMP, good manufacturing practices; GPCR, G
rotein-coupled receptors; HPBL, human peripheral blood lymphocytes; JECFA,
oint FAO/WHO Expert Committee on Food Additives; LC/MS, liquid chromatog-
aphy with mass spectrometry; MC,  methylcellulose; mnPCE, micronucleated bone
arrow polychromatic erythrocytes; MRM,  multiple-reaction monitoring; MSDI,
aximized survey-derived intake; MTD, maximum tolerated dose; NOAEL, no-
bserved-adverse-effect-level; NOEL, no-observed-effect-level; OECD, Organization
or Economic Cooperation and Development; PCE, polychromatic erythrocytes; PK,
harmacokinetics; SPET, single portion exposure technique; t1/2, half-life; Tmax, time
o  reach Cmax; TE, total erythrocytes; TK, toxicokinetics; Vss, volume of distribution
t  steady-state.
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214-7500/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Bitter taste is generally considered to be an undesirable taste
attribute in most food products and is believed to trigger an
innate stereotypical response to prevent mammals from intoxica-
tion by avoiding ingestion of potentially harmful food constituents.
Although a clear correlation between bitterness and toxicity has
not been established, many naturally occurring toxic compounds
induce a bitter-taste response [30,47]. However, many potentially
beneﬁcial constituents in certain fruits and vegetables such as
plant-based phenols and polyphenols, ﬂavonoids, isoﬂavones, ter-
penoids, and glucosinolates, have been described as having a bitter
taste quality [31,11]. One potential approach to improve the palata-
bility of foods with beneﬁcial phytonutrients is to attenuate their
bitter off-tastes with bitterness-masking compounds.
Bitter substances are detected by a speciﬁc subset of taste
receptor cells localized in the taste bud and characterized by the
expression of members of the hTAS2R family of G protein-coupled
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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eceptors (GPCRs) [1,7,34,37,2]. Humans have at least 25 full-length
TAS2Rs, clustered on 3 human chromosomes, which are highly
ivergent in sequence, sharing only 30–70% amino acid homology
27]. Additionally, there are more than 80 single nucleotide poly-
orphisms among individual hTAS2R genes [8,26], several of which
re responsible for the variation in the intensity of human bitter
aste perception to various bitter tastants [6,25,46,49]. Unlike most
PCRs, a single hTAS2R can recognize a diverse variety of chemical
ntities and most bitter tastants can activate multiple hTAS2Rs.
The discovery of the hTAS2Rs and recent development of
igh-throughput screening methods for hTAS2R antagonists have
nabled the development of potential bitterness-blocking agents
3–5]. Despite the characterization of the hTAS2Rs, which are
ctivated by various bitter tastants, and the growing commercial
nterest in developing bitter blockers to mask the bitter taste of
rugs and certain foods, relatively few synthetic inhibitors against
his class of GPCRs has been reported to date [48,18,28].
Researchers at Senomyx, Inc. have recently reported a
eries of novel substituted 3-(pyrazol-4-yl) imidazolidine-
,4-diones, including 3-(1-((3,5-dimethylisoxazol-4-yl)
ethyl)-1H-pyrazol-4-yl)-1-(3-hydroxybenzyl)imidazolidine-
,4-dione (S6821, CAS 1119831-25-2) and
-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-
3-hydroxybenzyl)-5,5-dimethylimidazolidine-2,4-dione (S7958,
AS 1217341-48-4), which are selective antagonists of the human
itter receptor hTAS2R8 (IC50’s = 0.035 and 0.073 M,  respectively)
23]. Both S6821 and S7958 have demonstrated the ability to sig-
iﬁcantly attenuate the bitter taste of a variety of bitter tastants
resent in consumer products including caffeine, rebaudioside A,
hey protein, and hydrolyzed soy protein. The structures of S6821
nd its 5,5-dimethyl analog S7958 are shown in Fig. 1.
Both S6821 and S7958 have been reviewed by the Expert Panel
f the Flavour and Extract Manufacturers Association of the United
tates (FEMA) and determined to be generally recognized as safe
GRAS) under conditions of intended use as a ﬂavour ingredient
33,19] and therefore are available for use in human food in the
nited States as “FEMA GRAS” ﬂavour ingredients. S6821 and S7958
ere assigned FEMA GRAS Numbers 4725 and 4726, respectively,
n 2010 [33]. S6821 and S7958 have also determined to be safe
t the current levels of intake by the Joint FAO/WHO Expert Com-
ittee on Food Additives [22] (assigned JECFA No. 2161 and 2162,
espectively) and S6821 has recently been submitted to the Euro-
ean Union for review. Other jurisdictions permit the use of S6821
ncluding Japan, Korea, and Mexico (794 DO 5.9.2013).
The purpose of this publication is to summarize the results
btained from in vitro metabolism and in vivo pharmacokinetic (PK)
tudies, general toxicology studies in rodents, developmental tox-
city studies, and genotoxicity studies conducted with S6821 and
7958. Additional supporting data obtained in these studies with
6821 and S7958 is included in a Supplementary Data section in
he online publication.
. Materials and methods
The batches of S6821 used for the in vivo metabolism and
8-day range-ﬁnding toxicity studies (Batch ID nos. 36881437
nd 37284090, respectively; purity >99%), were synthesized at
enomyx, San Diego, CA using the procedure described in US
atent 8,076,491 [23]. The batch of S6821 used for the in vitro
etabolism, in vivo PK, in vitro and in vivo genotoxicity, and 90-day
ubchronic toxicity studies (Batch ID no. 100968056, Lot no. CMLW-
85/09-EX2, purity 99.9%), was synthesized at Cambridge Major
aboratories, Germantown, WI  using the same synthetic method
ut prepared in conformance with GMPs as described in the ICH
MP  Guidelines for APIs [20]. The batch of S6821 used for the Reports 3 (2016) 310–327 311
range-ﬁnding and deﬁnitive developmental toxicity studies (Batch
ID no. 110280840, Lot no. 140491, purity 99.7%) was  synthesized
at Labochim, Milan, Italy, also according to GMP, using a slight
modiﬁcation of the same synthetic method.
The batch of the S7958 used for the in vivo metabolism, in vitro
genotoxicity and 28-day subchronic toxicity studies (Batch ID no.
44500878, purity >99%), was  synthesized at Senomyx, San Diego,
CA using the procedure described in US Patent 8,076,491 [23].
The experimental design for genetic toxicology studies followed
the OECD Guidelines for the Testing of Chemicals—471, 473, and
474 [39–41]. The 28- and 90-day toxicology studies in rats were
conducted in accordance with United States FDA Redbook 2000
[13]: IV.C.3.a. Short Term Toxicity Studies with Rodents [14], United
States FDA Redbook 2000: IV.C.4.a. Subchronic Toxicity Studies
with Rodents [15], and OECD Guidelines for Testing of Chemicals
Guidelines 407 and 408, Repeated Dose 28- or 90-Day Oral Toxicity
Study in Rodents [42,45]. All of the genetic toxicology and rodent
toxicity studies were also conducted in compliance with the UK
Good Laboratory Practice (GLP) regulations [35] and OECD guide-
lines [43]. The developmental toxicity range-ﬁnder and deﬁnitive
studies were conducted in accordance with the OECD Guidelines for
Testing of Chemicals Guideline 414, Prenatal Developmental Tox-
icity Study [44] and the United States FDA Redbook 2000: IV.C.9.b
Guidelines for Developmental Toxicity Studies [13]; the deﬁnitive
study was also conducted in compliance with the FDA GLP regula-
tions 21CFR Part 58 and OECD guidelines [43].
The receptor panel proﬁling and preliminary cytochrome P450
(CYP) inhibition assays were conducted at MDS  Pharma Services,
Taipei, Taiwan; the follow-up CYP inhibition assays were carried
out by Ricerca Biosciences, Bothell, WA using pooled human liver
microsomes prepared by XenoTech, Lenexa, KS. The hERG channel
inhibition assay was  carried out by Aviva Biosciences, San Diego,
CA. The in vitro microsomal metabolism and pharmacokinetic (PK)
studies were carried out by Huntington Life Sciences (HLS), Cam-
bridgeshire, UK. The microsomal metabolism studies utilized rat
liver microsomes prepared in-house at HLS; human microsomes
were from a pool of 50 donors and were obtained from BD Bio-
sciences (Cat. No. 452156, lot 88114). The bioanalysis for the S6821
PK study was carried out by Nuvisan Pharma Services GmbH, Neu-
Ulm, Germany. The in vivo metabolism studies on S6821 and S7958
were conducted at Senomyx, San Diego, CA. The analytical methods
used for the PK and in vivo metabolism studies can be found in the
Supplementary Data section published online.
All genotoxicity and rodent toxicology studies for both S6821
and S7958 were conducted at HLS, Suffolk and Cambridgeshire,
UK. The strains of Salmonella typhimurium used in the reverse bac-
terial mutation assay were obtained from the National Collection
of Type Cultures, London, England; the strain of Escherichia coli
was obtained from the National Collections of Industrial and
Marine Bacteria, Aberdeen, Scotland. Cultures of human lympho-
cytes for the chromosome aberration test were prepared from
pooled blood collected aseptically from two, healthy, non-smoking
donors. The developmental toxicity study on S6821 was conducted
at WIL  Research, Ashland, OH. A description of the study designs
is included in the individual study sections below. Detailed data
tables for the genotoxicity, subchronic and developmental toxicity
studies can be found in the Supplementary Data section published
online.
3. In vitro receptor and cytochrome P450 proﬁling of S6821
and S7958In vitro tests were conducted with S6821 and S7958 to assess
whether the compounds interact with any enzymes or receptors
that might cause adverse or unexpected effects or affect drug
312 D.S. Karanewsky et al. / Toxicology Reports 3 (2016) 310–327
Fig. 1. Structures of S6821 and S7958.
Table 1
Cytochrome P450 Inhibition of S6821 and S7958.
Cmpd CYP Spectroﬂuorimetric assay, human recombinant enzymes, Sf9 cells LC–MS/MS assay in human liver microsomes
Probe Substrate % Inhibition (10 M)  Probe Substrate % Inhibition (10 M)
S6821 1A2 3-cyano-7-ethoxycoumarin 3% phenacetin 18%
2C9  3-cyano-7-ethoxycoumarin 34% tolbutamide −3%
2C19  3-cyano-7-ethoxycoumarin 26% S-mephenytoin 8%
2D6  3-cyano-7-ethoxycoumarin 8% bufuralol −2%
3A4  7-benzyloxy-4- (triﬂuoromethyl)-coumarin 1% midazolam 4%
S7958 1A2  3-cyano-7-ethoxycoumarin 1% ethoxyresoruﬁn 16%
2C9  3-cyano-7-ethoxycoumarin 80% tolbutamide 62%
11%
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etabolism. Preliminary in vitro screening for potential off-target
ctivity of S6821 and S7958 included tests for CYP inhibition, a lead
roﬁling receptor screen (a panel of 68 receptor binding assays for
PCRs, ion channels, nuclear receptors, transporters), and a hERG
nhibition assay. The preliminary tests for CYP inhibition were per-
ormed using recombinant human enzymes expressed in insect Sf9
ells using spectroﬂuorimetric substrates [9,36]. All assays were
erformed at a concentration of 10 M of either S6821 or S7958. No
igniﬁcant responses (≥50% inhibition or stimulation) were found
ith either compound in the lead proﬁling receptor screen. Nei-
her S6821 nor S7958 signiﬁcantly inhibited the hERG ion channel
urrent (<10%) in an in vitro hERG electrophysiology (patch clamp)
ssay [50]. The results from the CYP inhibition studies are summa-
ized in Table 1.
As a follow up to the results obtained using spectroﬂuorimetic
ubstrates, S6821 and S7958 were retested on the same panel of
YP enzymes utilizing pooled human liver microsomes and CYP-
peciﬁc substrates with detection of the CYP-speciﬁc metabolites
y LC–MS/MS [29,51]. S6821 did not signiﬁcantly inhibit any of
he CYP isozymes in either assay format. In contrast, 10 M of
7958 demonstrated signiﬁcant inhibition of CYP2C9 in both the
pectroﬂuorimetric and LC–MS/MS assays (see Table 1). In a sep-
rate study, S7958 was also evaluated for evidence of time-and
etabolism-dependent inhibition of CYP2C9 again using pooled
uman liver microsomes and diclofenac as a CYP2C9 substrate. To
valuate time- and metabolism-dependent inhibition, S7958 was
reincubated with human liver microsomes in the presence and
bsence of a NADPH-generating system for 30 min prior to incuba-
ion with the marker substrate. In this assay format, S7958 was a
irect inhibitor of CYP2C9 with an IC50 value of 8.8 M.  In addition,
here was no evidence of either time- or metabolism-dependent
nhibition of CYP2C9 by S7958.
. Absorption, distribution, metabolism, excretionThe in vitro metabolism of S6821 was studied using rat and
uman liver microsomes. The in vivo metabolism of both S6821
nd S7958 was studied in rats. A complete PK study of S6821 and
ts major metabolites was carried out in male Sprague-Dawley rats. S-mephenytoin 17%
bufuralol 17%
 midazolam 12%
4.1. In vitro metabolism of S6821
The potential of S6821 to undergo oxidative metabolism was
investigated using Sprague-Dawley rat and human liver micro-
somes in order to determine the similarity of the metabolic proﬁle
across these species. Reference standards were synthesized for the
three potential oxidative metabolites that could be produced by
mono-hydroxylation of the 3-hydroxybenzyl moiety (see Fig. 2).
S6821 (1, 10, and 50 M)  was incubated with mixed gender, pooled
rat and human liver microsomes (0.5 mg/mL) in the presence of
NADPH at 37 ◦C for 0, 10, 30 or 120 min  prior to quenching the
samples with acetonitrile. Control incubations in the absence of
microsomes were conducted in parallel, for 120 min  only, at all
substrate concentrations. [14C]Testosterone (53 mCi/mmol) was
tested in parallel with S6821 to conﬁrm the functionality of the
microsomes (10 min  incubation). Samples were centrifuged to sep-
arate the precipitated microsomes from the supernatant containing
the parent compound and it metabolites. The supernatants from
the S6821 incubations were analyzed by liquid chromatography-
mass spectrometry (LC–MS) using a Waters Symmetry C18 column
(150 × 3.9 mm)  with 0.1% formic acid and acetonitrile gradient
system, and a TSQ7000 mass spectrometer operated in positive
ionization mode. The samples were scanned in the positive ioniza-
tion mode for metabolites with +16 mass units greater than parent
(mono-hydroxy metabolites), +18 mass units greater than parent
(hydantoin ring opened metabolites), +32 mass units greater than
parent (dihydroxy metabolites), and masses of 276 (loss of hydrox-
ybenzyl), 207 (loss of dimethylisoxazol-pyrazole group), and 273
(loss of dimethylisoxazole group). Positive control incubations with
[14C]testosterone were analyzed using an Agilent 1200 series HPLC,
monitoring for UV absorbance at 254 nm using an Agilent 1200
series variable wavelength detector, and for 14C-radioactivity using
a -Ram Radioisotope System. There was  greater than 30% turnover
of testosterone in parallel incubations with microsomes of both
species. Details of the experimental and analytical methods can be
found in the Supplementary Data section.
The extent of metabolism (loss of parent S6821) was  generally
greater by rat than by human liver microsomes, but more detectable
mono-hydroxylated metabolites were seen in incubations with
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Fig. 2. Structures of S6821 Major Microsomal and In Vivo Metabolites.
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he later. However, dihydroxylated and other degradation prod-
cts were not detected in either the rat or human liver microsome
ncubation samples. At the 120 min  time point in the human micro-
ome incubations with 50 M of S6821, 75% of the initial S6821
as remaining based on MS  peak areas. Human liver microsomes
ormed at least four identiﬁable mono-hydroxylated metabolites
hich in total represented 23% of the initial S6821 peak area.
wo are hydroxylated on the phenyl ring, M397A and M397B. The
tructures were conﬁrmed by LC/MS comparison to reference stan-
ards (see Fig. 2). The corresponding 2,3-dihydroxybenzyl analog
397C was not observed in the human microsomal incubations but
as subsequently identiﬁed as an in vivo metabolite in rats (vide
nfra). The other two metabolites, M397D and M397E, were mono-
ydroxylated at undetermined positions on the dimethylisoxazole
ing as conﬁrmed by product ion mass spectra. The mass spectral
ragmentation patterns for S6821 and its hydroxlyated metabolites
397A-E are shown in Fig. 3. At the 120 min  time point in thethway for S6821 and M397A-E.
rat microsome incubations with 50 M of S6821, 56% of the initial
S6821 was  remaining based on mass spec peak areas. LC–MS results
indicate that rat liver microsomes formed primarily one mono-
hydroxylated metabolite of S6821 identiﬁed as M397D, one of the
metabolites observed in the human microsomal incubations which
is hydroxylated on the dimethylisoxazole ring. At the 120 minute
time point in the incubations with 50 M S6821, M397D only rep-
resented 0.5% of the initial S6821 peak area.
4.2. In vivo metabolism of S6821 and S7958 in rats
The in vivo metabolism of S6821 and S7958 was  evaluated fol-
lowing a single oral administration in male Sprague-Dawley rats. A
group of 4 male Sprague-Dawley [Crl:CD®(SD)] rats (Charles River
Laboratories, Hollister, CA) was administered either 100 mg/kg bw
of S6821 or 30 mg/kg bw of S7958 in 1% methylcellulose by oral
gavage. Blood samples were taken at approximately 30 min, 2, and
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 h post-dose for animals dosed with S6821, and at 30 min, 2, 4, 8,
nd 24 h post-dose for animals treated with S7958. Plasma sam-
les were analyzed for the parent compounds and metabolites by
C–MS/MS using a HALO RP-amide column (150 × 3.0 mm,  2.7 um)
ith a 0.1% formic acid and methanol gradient system, and an
BI API 3200 mass spectrometer operated in positive ionization
ode. S7958 served as an internal standard for the plasma samples
rom animals dosed with S6821, and S6821 served as an internal
tandard for animals dosed with S7958. Details of the analytical
ethods can be found in the Supplementary Data section.
In the case of the plasma samples from animals treated with
6821, the parent compound and the internal standard (S7958)
ere detected using a source which was conﬁgured with tur-
oionspray ionization in the positive mode using multiple-reaction
onitoring (MRM)  of mass transition pairs at m/z  of 382.2/110.1
nd 410.2/110.1 amu. Peak area ratios of S6821 to the internal
tandard (S7958) were used to quantify the samples. The max-
mum concentration of S6821 in rat plasma was  observed at
he 0.5 h time point in all the test animals (mean concentra-
ion: 105.4 ± 68.2 ng/mL). In addition to the expected S6821 peak
n the extracted ion chromatogram (EIC) in the plasma sam-
les monitored by the 382 → 110 MRM  transition, two additional
ajor metabolite peaks were observed. The spectra from enhanced
roduct ion (EPI) scans and enhanced MS  (EMS) scans are consis-
ent with the corresponding glucuronide M557 (M + H: m/z 558;
 + Na: m/z 580) and sulfate M461 (M + H: m/z 462; M + Na: m/z
84) conjugates of S6821. The structures of these Phase II metabo-
ites were conﬁrmed by direct comparison to synthetic standards
see Fig. 2). Both secondary metabolites are present at signiﬁcantly
igher concentrations than the parent S6821 throughout the 4 h
ost-dosing period. During the observation period, the mean con-
entrations of M557 and M461 in the plasma samples ranged from
2 to 166 ng/mL and 334–555 ng/mL, respectively.
The mono-hydroxylated metabolites of S6821 were detected
sing a source which was conﬁgured with turboionspray ionization
n the positive mode using MRM  of mass transition pair at m/z of
98.2/110.1 amu. Of the three possible benzyl mono-hydroxylation
roducts of S6821, only M397C was conﬁrmed to be present in rat
lasma. The mean concentrations of M397C in the plasma samples
ere in the range of 12.6–18.9 ng/mL throughout the observation
eriod. This mono-hydroxylation product was not observed in the
at microsomal incubations. Two additional peaks were present in
he 398.2/110.1 MRM  chromatogram that did not co-elute with the
ther possible benzyl mono-hydroxylation products M397A and
397B. They were also present in the MRM  chromatograms moni-
ored for the 478 → 110 transition suggesting that they may  be the
ulfate derivatives of the benzyl mono-hydroxylated metabolites
477A/B. The position of the hydroxylation and that of the sulfate
oiety are unknown at this time.
In addition to the benzyl mono-hydroxylated metabolites of
6821 described above, three others were detected using MRM  of
ass transition pair at m/z of 398.2/126.2 amu. The 398 → 126 tran-
ition is consistent with metabolites in which the isoxazole ring of
6821 has undergone hydroxylation. All three of these peaks are
lso present in the MRM  chromatogram when monitored for the
98 → 273 transition conﬁrming the site of hydroxylation. Two  of
hese peaks are likely the same isoxazole-hydroxylated metabo-
ites M397D and M397E observed in the rat and human microsomal
ncubations. One of the three peaks was also present in the MRM
hromatogram when monitored for the 478 → 126 transition sug-
esting that it is a sulfate derivative of an isoxazole-hydroxylated
etabolite M477C. The position of the hydroxylation and that
f the sulfate moiety are unknown at this time. Based on EIC
eak areas, one of the two sulfated mono-hydroxylated metabo-
ites M477A/B, is present at 3–4 fold higher concentration than
397C; all of the other metabolites (M397D/E and M477C) appear Reports 3 (2016) 310–327
to be in signiﬁcantly lower amounts than M397C. As stated above,
the mono-hydroxylated compounds M397A and M397B were not
observed in rat plasma, but may  be the biosynthetic precursors of
sulfates M477A/B. The metabolic pathway of S6821 in rats is shown
in Fig. 4.
The plasma samples from the animals treated with S7958 were
analyzed by LC–MS/MS by methods analogous to those used for the
plasma samples from animals treated with S6821. The maximum
concentration of S7958 in rat plasma throughout the observa-
tion period was  only 5.2 ± 7.1 ng/mL. Due to the limited number
of animals tested and the large ﬂuctuation of the S7958 con-
centration between the animals, the Tmax for S7958 could only
be estimated to occur between 2 and 8 h. Mass ion transition
pairs at m/z of 426.2/110.1, 490.2/110.1, and 586.3/110.1 amu
were used to detect the mono-hydroxylated, O-sulfated, and O-
glucuronidated metabolites of S7958, respectively. Ions consistent
with the presence of S7958 glucuronide and sulfate metabolites
as well as a sulfate derivative of a mono-hydroxylated metabolite
were observed in the extracted ion chromatograms of the plasma
samples. Although plasma concentrations of the parent compound
S7958 are signiﬁcantly less than those seen with S6821, S7958
demonstrates an overall metabolism proﬁle similar to that of its
close analogue S6821.
4.3. Pharmacokinetics of S6821 in rats
The PK parameters and oral bioavailability of S6821 in plasma
was evaluated following either a single intravenous or oral admin-
istration in male Sprague-Dawley [Crl:CD®(SD)] rats (Charles River
UK Ltd, Margate, Kent, England). Plasma samples were also ana-
lyzed for the presence of the sulfate M461 and glucuronide M557
conjugates observed in the preliminary in vivo metabolism study in
rats. For intravenous administration, 6 male Sprague-Dawley rats
were bolus injected with S6821 at 1 mg/kg bw in PEG 300:puriﬁed
water (1:1). For oral administration, 6 male Sprague-Dawley rats
per group were administered S6821 at either 10, 30, or 100 mg/kg
bw in PEG 300:puriﬁed water (1:1) by oral gavage. Blood samples
were collected by venipuncture of a caudal vein at approximately
15, 30 min, 1, 2, 4, 8, 12, 24, and 48 h post-dose at alternating
time points from two  cohorts of 3 animals/dose group with an
additional time point (5 min) for the intravenously treated ani-
mals. Plasma samples spiked with S7958 as an internal standard
were analyzed for S6821 and metabolites by LC–MS/MS using
a HALO RP-amide column (150 × 3.0 mm,  2.7 um)  with a 0.1%
formic acid and methanol gradient system and a Sciex API 3000
mass spectrometer operated in positive ionization mode. The par-
ent compound, internal standard, and metabolites were detected
using a source which was conﬁgured with turboionspray ioniza-
tion in the positive mode using MRM  of mass transition pairs at
m/z of 382.2/110.1 (S6821, M461, M557) and 410.2/110.1 (S7958)
amu. Details of the analytical methods can be found in the Sup-
plementary Data section. Test article formulations prepared for
this study were analyzed for concentration by LC–MS/MS. The PK
parameters were analysed by non-compartmental methods using
WinNonlin Pro version 5.0 software (Pharsight Corporation, USA).
The pharmacokinetic parameters for S6821 and its sulfate M461
and glucuronide M557 conjugates are shown in Table 2.
Both S6821 and its glucuronide conjugate M557 were rapidly
eliminated after intravenous administration with terminal half-
lives (t1/2) of 0.1 and 0.2 h, respectively. The terminal t1/2 of
the sulfate conjugate M461 however, was  longer than that of
S6821 (1.9 h) indicating that the rate of formation of M461 was
not the rate-limiting step in its elimination. Mean maximum
plasma concentrations of 3380 and 315 ng/mL for M461 and
M557 respectively, occurred at 5 min  post dose. Systemic expo-
sure (AUClast) was  found to be highest for metabolite M461 while
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Fig. 4. Metabolic Pathway of S6821 in Rat.
Table 2
Pharmacokinetics of S6821, M461, and M557 in Male Sprague-Dawley Rats Treated with S6821.
Route Dose (mg/kg bw)  Analyte Cmax (ng/mL) Tmax (h) t1/2 (h) AUC0-last (ng·h/mL) AUC0-last/dose (ng·h/mL/mg/kg) %F
iv 1.0 S6821 619 0.08 0.1 161 161 –
M461 3380 0.08 1.9 4500 4500 –
M557 315 0.08 0.2 104 104 –
oral  gavage 10 S6821 12.3 0.5 2.0 28.0 2.80 1.74%
M461 2600 0.5 2.9 18200 1820 –
M557 2540 1.0 1.4 6050 605 –
30 S6821  38.5 0.5 7.1 201 6.70 4.16%
M461 4620 0.5 2.5 32000 1070 –
M557 8050 0.5 1.7 22900 763 –
100 S6821  68.1 0.5 4.3 410 4.10 2.55%
M461 6110 4.0 4.7 72500 725 –
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6821: CL = 105 mL/min/kg; Vss = 563 mL/kg CL = clearance; Vss = steady-state volum
he exposure to S6821 and glucuronide M557 were similar. The
ean plasma clearance (CL) of S6821 after an intravenous dose
as 190% (105 mL/min/kg) of the hepatic blood ﬂow in the rat
55.2 mL/min/kg [10]), and the volume of distribution at steady
tate (Vss) was 0.84 times (563 mL/kg) the total body water volume
n the rat (668 mL/kg [10]). A plot of the mean plasma concen-
rations of S6821, M461 and M557 verses time after intravenous
dministration of S6821 is shown in Fig. 5.
Following oral gavage administration of S6821 to male rats at
0 mg/kg bw, absorption was rapid and the mean maximum S6821
lasma concentration (Cmax) of 12.3 ng/mL occurred 0.5 h post
ose. Following administration of S6821 at 30 and 100 mg/kg bw,
he mean maximum plasma concentrations of S6821 were 38.5
nd 68.1 ng/mL respectively, occurring at 0.5 h post dose. S6821
lasma concentrations increased with increasing oral doses from
0 to 100 mg/kg bw and the rate and extent of systemic expo-
ure, as reﬂected by the parameters Cmax and AUClast respectively,
ncreased with increasing dose. However, these increases were
ot proportionate to the dose increase. At the highest dose level
100 mg/kg bw), Cmax was 45% lower than that predicted by a lin-
ar relationship. At this dose, the increase in systemic exposure
AUClast) was more than proportionate to the dose increase and was
lmost 1.5-fold higher than that predicted by a linear relationship.4.2 44700 447 –
stribution; %F = bioavailability.
The systemic bioavailability of S6821 following oral administration
was low, with percentage values (%F) of 1.74%, 4.16% and 2.55%
following oral doses of 10, 30 and 100 mg/kg bw respectively.
Metabolism of S6821 to sulfate M461 was  rapid with Cmax val-
ues of 2600 and 4620 ng/mL occurring at 0.5 h post dose following
administration of S6821 at 10 and 30 mg/kg bw respectively. Fol-
lowing S6821 administration at 100 mg/kg bw the mean maximum
plasma M461 concentration of 6110 ng/mL occurred at 4 h post
dose. The terminal t1/2 of metabolite M461 following oral doses of
S6821 at 10, 30 and 100 mg/kg bw, was 2.9, 2.5 and 4.7 h respec-
tively, compared to a terminal t1/2 of 1.9 h after intravenous bolus
dose administration of S6821. The systemic exposure of M461
ranged from 160- to 650-fold higher than that of S6821. Similarly,
metabolism of S6821 to M557 was also rapid at all dose levels with
Cmax occurring between 0.5 and 1 h post dose. Following adminis-
tration of S6821 at 10, 30 and 100 mg/kg bw,  the mean maximum
plasma concentrations of M557 were 2540, 8050 and 9090 ng/mL
respectively. The terminal t1/2 of metabolite M557 was  1.4, 1.7
and 4.2 h following oral doses of 10, 30 and 100 mg/kg bw S6821,
compared to a terminal t1/2 of 0.2 h after intravenous bolus dose
administration of S6821. The systemic exposure of M557 ranged
from 109- to 216-fold higher than that of S6821. A plot of the mean
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Fig. 5. Mean plasma concentrations of S6821, M461, and M557 after intravenous administration of S6821 (1.0 mg/kg bw) to male S-D rats.
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lasma concentrations of S6821, M461 and M557 verses time after
ral administration of S6821 (100 mg/kg bw)  is shown in Fig. 6.
Both Cmax and AUClast for M461 and M557 increased with
ncreasing dose of S6821 over the range 10–100 mg/kg bw S6821.
owever, these increases were less than the proportionate dose
ncrease. At the highest dose level, the Cmax and AUClast values
or M461 were approximately 76% and 60% lower than the values
redicted by a linear relationship, respectively. Similarly, Cmax and
UClast values for M557 at this dose level were approximately 64%
nd 26% lower than the value predicted by a linear relationship,
espectively.
. Genotoxicity and mutagenicity studies
S6821 was evaluated for its genotoxic potential through a stan-
ard (5-strain) Ames, chromosome aberration, and micronucleus
ests (see Table 3). A reverse bacterial mutation assay was also con-
ucted on S7958. All genetic toxicology studies were conducted in
ompliance with the United States Food and Drug Administration
FDA) Good Laboratory Practices (GLP) regulations 21CFR Part 58(ho urs)
 oral administration of S6821 (100 mg/kg bw) to male S-D rats.
[17] and OECD guidelines [43]. The data tables for the genotoxicity
studies can be found in the Supplemental Material.
5.1. Bacterial reverse mutation test (5-Strain ames)
S6821 and S7958 were evaluated for the potential to induce
point mutations in S. typhimurium strains TA98, TA100, TA1535,
TA1537 and E. coli strain WP2  uvrA in the presence and absence of
metabolic activation with rat liver S9 from rats induced with pheno-
barbital and 5,6-benzoﬂavone. The assay was  designed to meet the
current OECD Guideline for Testing of Chemicals No. 471, Bacterial
Reverse Mutation Test [39].
The concentrations of S6821 and S7958 investigated for both
the plate incorporation and pre-incubation tests ranged from 50
to 5000 g per plate. In both the plate incorporation and pre-
incubation assays, toxicity was  not observed at any concentration
of either compound as evident by a normal background lawn
and colony counts similar to the concurrent negative controls.
No precipitates were observed in any of the plates containing
S6821. Precipitate was observed on all plates containing S7958 at
5000 g/plate in both the absence and presence of S9 mix, and at
1500 g/plate in the absence of S9 mix, in both tests. Neither S6821
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Table  3
Summary of genotoxicity studies conducted on S6821 and S7958.
End-Point Test System Cmpd No. Concentration/Dose Result
Reverse mutation
(in vitro)
S. typhimurium strains TA98, TA100, TA1535,
TA1537 and E. coli strain WP2  uvrA
S6821 50–5000 g/plate, plate incorporation and
pre-incubation, ±S9a
Negative
S7958 50–5000 g/plate, plate incorporation and
pre-incubation, ±S9a
Negative
Chromosome aberration (in vitro) Primary human lymphocytes S6821 297–824 g/mL, 3 hr exposure −S9
297–824 g/mL, 3 hr exposure +S9a (2%)
1100–1300 g/mL, 3 hr exposure +S9a (5%)
200–600 g/mL, 21 hr exposure −S9
Negative
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[Micronucleus formation (in vivo) Male Swiss albino mice (CD-1), bone marro
a S9 from rat liver homogenate from male Sprague-Dawley rats treated with phe
or S7958 increased the number of revertant colonies in either the
late incorporation or pre-incubation assays with any of the tester
trains both in the presence and absence of metabolic activation
ith rat liver S9. The concurrent positive controls demonstrated
he sensitivity of the assay and the metabolizing activity of the liver
reparations. Thus, it was concluded that both S6821 and S7958
ere not mutagenic to S. typhimurium strains TA98, TA100, TA1535,
A1537 and E. coli strain, WP2  uvrA in the absence and presence of
etabolic activation under the test conditions employed.
.2. In vitro chromosome aberration test
S6821 was investigated for its potential to induce structural
nd numerical chromosome aberrations in human peripheral blood
ymphocytes (HPBL), both in the presence and absence of a supple-
ental rat liver fraction (S9) from rats induced with phenobarbital
nd 5,6-benzoﬂavone. Solvent and positive control (mitomycin C,
S9; cyclophosphamide, +S9) cultures were also included. The
xperimental design followed the OECD Guideline for the Testing
f Chemicals No. 473, In Vitro Mammalian Chromosome Aberration
est [40]. In order to determine the toxicity of S6821 to cultured
PBL, the mitotic index was assessed for all cultures treated with
he test substance in the presence and absence of S9, as well as that
f the solvent control, dimethyl sulfoxide (DMSO).
On the basis of these data, the doses chosen for the chro-
osome aberration assay ranged from 297 to 824 g/mL for the
on-activated and S9-activated (2% v/v) 3-hour exposure groups,
rom 1100 to 1300 g/mL for the S9-activated (5% v/v) 3-hour
xposure group, and from 200 to 600 g/mL for the non-activated
1-hour exposure group. All conditions were tested at the limit of
est article toxicity as assessed by the Relative Mitotic Index (RMI
47% under all conditions).
Under these test conditions, no structural or numerical chro-
osome aberrations were observed in the S6821 treated cultures
eyond those seen in the concurrent solvent controls. All concur-
ent positive controls induced signiﬁcant numbers (p < 0.001) of
ells with chromosome aberrations. It was concluded that expo-
ure to S6821 did not induce chromosome aberrations in the in vitro
ammalian chromosome aberration test using HPBL in both the
bsence and presence of rat liver S9, when tested in accordance
ith regulatory guidelines.
.3. In vivo micronucleus assay in mice
S6821 was evaluated for potential in vivo clastogenic activity
nd/or disruption of the mitotic apparatus, as measured by its
bility to increase the incidence of micronucleated polychromatic
rythrocytes (mnPCEs) in the bone marrow of CD-1 mice. The study
as designed to meet the current OECD Guideline for the Testing
f Chemicals No. 474, Mammalian Erythrocyte Micronucleus Test
41]. A dose-range ﬁnding study was performed to assess test arti-s S6821 500, 1000, 2000 mg/kg bw/day (oral), 2 days Negative
bital/5,6-benzoﬂavone.
cles toxicity and determine the maximum tolerated dose (MTD) or
maximum feasible dose (MFD) for the deﬁnitive assay.
For the dose range ﬁnding phase of the study, male and female (2
animals/sex/group) Crl:CD-1(ICR) mice (Charles River UK Ltd, Mar-
gate, Kent, England) were treated with 2000 mg/kg bw of S6821
suspended in vehicle (1% methylcellulose (MC) in puriﬁed water)
at a volume of 10 mL/kg body weight for two consecutive days,
approximately 24 h apart, by oral gavage. Since there was no tox-
icity noted up to 2000 mg/kg bw,  dose levels of 500, 1000, and
2000 mg/kg bw (6 animals/group), were used for the deﬁnitive
study with S6821. Since no substantial differences in toxicity were
observed between the sexes, the main test was performed using
male animals only. In the deﬁnitive phase of the study, 1% MC  was
used as the vehicle (negative) control and mitomycin C, at a dose
of 12 mg/kg bw (dose volume 20 mL/kg), was  used as the positive
control article. Animals were observed for signs of toxicity during
the course of these studies.
In the deﬁnitive assay, all animals from each of the test article
and vehicle treated groups were euthanized 24 h after administra-
tion of the second dose by carbon dioxide inhalation; animals in
the positive control group were sacriﬁced 24 h after a single dose.
Immediately following euthanasia, femoral bone marrow was  col-
lected from each animal. Bone marrow slides were prepared and
polychromatic erythrocytes (PCEs, 2000/animal) were examined
microscopically for the presence of micronuclei (mnPCEs). The ratio
of PCEs to total erythrocytes (TE) in the test article groups relative
to the vehicle control groups was also evaluated to reﬂect the test
article’s cytotoxicity.
No clinical signs of toxicity were noted for the vehicle control,
positive control and S6821 group animals over the duration of the
test. Some small incidences of bodyweight loss were observed in all
study groups. No statistically signiﬁcant reductions in the PCE/TE
ratio in the S6821 treated groups compared to the vehicle control
group were observed indicating that the test article did not induce
cytotoxicity. No statistically signiﬁcant increase in the incidence of
mnPCEs in the S6821 treated groups was  observed relative to the
negative control group. The positive control (mitomycin C) induced
statistically signiﬁcant increases in the incidence of mnPCEs when
compared to both the negative control groups and the test article
treated groups at all three dose levels (p < 0.01). It was concluded
that oral administration of S6821 did not induce micronuclei or
bone marrow toxicity in male CD-1 mice when tested in accordance
with regulatory guidelines.
6. In vivo toxicological studies
S6821 was  evaluated in 28-day dose-range ﬁnding and 90-day
subchronic toxicology studies in rats in compliance with the FDA
Guidelines [16] Toxicological Principles for the Safety of Food Ingre-
dients. S7958 was evaluated in a 28-day subacute toxicology study
in rats. S6821 was also evaluated for potential embryo/fetal tox-
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city in a gestational developmental toxicity study in rats. The
evelopmental toxicity study consisted of two phases, a range-
nding study and a deﬁnitive study in which the test animals were
valuated for both maternal toxicity and effects on embryo/fetal
evelopment (see Table 4). Summary data tables for the 28-day
oxicology study for S7958, and for the 90-day toxicology and the
eﬁnitive developmental toxicity studies for S6821 can be found in
he Supplemental Material.
.1. Rodent toxicology studies
.1.1. 28-Day dose-range ﬁnding toxicity study on S6821
The purpose of this study was to evaluate the potential systemic
oxicity of S6821 in rats after dietary administration for 28 days
n order to select doses for 90-day subchronic toxicity study in
ats. Three treatment groups of male and female CD® [Crl:CD®(SD)]
ats (n = 5/sex/group, Charles River UK Ltd, Margate, Kent, Eng-
and) were administered S6821 in the diet at dose levels of 10,
0, or 100 mg/kg bw/day. One additional group of ﬁve animals/sex
erved as the control and received the vehicle diet. The test sub-
tance was administered continuously via the diet throughout the
8-day treatment period. Dietary concentrations (ppm) of S6821
or each group were adjusted each week based on bodyweight
nd food consumption data, in order to achieve constant doses in
erms of mg/kg bw/day. At the conclusion of the study, animals
ere sacriﬁced by carbon dioxide asphyxiation before subsequent
xsanguination. Survival, clinical observations, body weight, food
onsumption, hematology, clinical chemistry, organ weights, and
acroscopic evaluations of all animals were used to assess poten-
ial toxicity. The livers were examined microscopically for animals
n the 0 and 100 mg/kg bw/day dose groups.
Administration of S6821 in the diet for 28 days was well toler-
ted in rats at dose levels up to 100 mg/kg bw/day, the highest dose
ested. There was no test article-related mortality observed and all
nimals survived until scheduled euthanasia. There were no test
rticle-related clinical signs or changes in mean body weight, body
eight gain, food consumption, hematology parameters, coagula-
ion parameters, red blood cell morphology, or clinical chemistry
arameters during this study. In the high dose females, there was
 slight reduction of hematocrit, hemoglobin concentration and
rythrocyte count, compared with the controls. Plasma calcium
oncentrations were low at all doses in males (p < 0.01) and at
00 mg/kg bw/day in females (p < 0.05), and phosphate concen-
rations were also low in females receiving 100 mg/kg bw/day
p < 0.05). However, these differences were minor and the major-
ty of the individual values were within the laboratory’s historical
ontrol values and were therefore attributed to normal biological
ariation.
There were no test article-related gross observations, changes
n absolute or relative organ weights, or microscopic ﬁndings
bserved in the livers of the high dose animals examined at study
ermination. Based on these results, MTD  was considered to be
100 mg/kg bw/day (highest dose tested).
.1.2. 90-Day subchronic toxicity study on S6821
The purpose of this study was to evaluate the potential sub-
hronic toxicity and toxicokinetic (TK) proﬁle of S6821, in rats after
dministration for 90 consecutive days. Test article was admin-
stered in the diet to four groups of twenty male and twenty
emale Sprague-Dawley [Crl:CD®(SD)] rats (Charles River UK Ltd,
argate, Kent, England) at dose levels of 0 (control), 10, 30, or
00 mg/kg bw/day for 90 consecutive days. The test substance was
dministered continuously via the diet throughout the treatment
eriod. Dietary concentrations (ppm) of S6821 for each group were
djusted each week based on bodyweight and food consumption
ata, in order to achieve constant doses in terms of mg/kg bw/day. Reports 3 (2016) 310–327
For the purpose of the collection of the data for several of the
study parameters, the animals were divided into two  cohorts of
10 animals/sex/dose group (Cohorts A and B). At the conclusion of
the study, animals were sacriﬁced by carbon dioxide asphyxiation
before subsequent exsanguination.
Survival, clinical observations, body weight gain, food consump-
tion, hematology, clinical chemistry, urinalysis, organ weights,
macroscopic examination, and histopathologic evaluation were
performed to assess potential toxicity. A sensory reactivity and
motor activity assessment (including, but not limited to, evalua-
tion of motor activity, arousal, auditory startle response, tail pinch
response, and grip strength) was conducted during 12th week of
test article administration for all animals in Cohort A. Opthalmo-
scopic examinations were conducted pre-dose and during 12th
week of test article administration for animals in the control and
high dose groups in Cohort A. Samples for hematology, coagulation,
and clinical chemistry evaluations were collected from all animals
in Cohort A on Day 14, and during Weeks 7 and 13. Samples for uri-
nalysis evaluations were collected from all animals during Week
12. Blood for TK analysis was  collected on Day 7 and during Weeks
6 and 13 at six time points (each separated by 2 h) at alternating
time points from three groups of 3 animals/sex/dose group from the
animals in Cohort B. Microscopic examination of ﬁxed hematoxylin
and eosin-stained parafﬁn sections were performed on sections of
tissues from the control and high-dose (100 mg/kg bw/day) groups
from both Cohorts A and B. For organ weight data, analysis of covari-
ance was performed using terminal bodyweight as covariate. The
treatment comparisons were made on adjusted group means in
order to allow for differences in bodyweight which might inﬂuence
the organ weights.
The blood samples taken on Day 7 and during Week 6 and Week
13 of the 90-day toxicity study were used to assess the systemic
exposure of male and female rats to S6821 administered in diet.
Plasma concentrations of S6821 in samples taken at 6 time points
over a 24-hour period were measured by a validated LC–MS/MS
method. Maximum mean plasma concentrations (Cmax) of S6821
and areas under the mean plasma S6821 concentration-time curves
estimated over a 24-hour interval (AUC0-24h) on Day 7 and during
Week 6 and Week 13 are summarized in Table 5. Consistent with
the results of the single dose PK study in rats where S6821 was
administered by oral gavage, systemic exposure to S6821 was very
low. For example, at the 100 mg/kg bw/day dose, Cmax of S6821
ranged from 95.6 to 107 ng/mL (0.251–0.281 M)  in females, and
from 41.4 to 54.7 ng/mL (0.109–0.143 M)  in males, throughout the
duration of the study.
The rate (Cmax) and extent (AUC0-24h) of systemic exposure of
rats to S6821 on Day 7 and during Week 6 and Week 13 increased
with increasing dose over the nominal dose range 10–100 mg/kg
bw/day. In males, however, these increases were less than the pro-
portionate dose increment and at the highest nominal dose level
(100 mg/kg bw/day) the Cmax and AUC0-24h values were ca 32%
lower than those values predicted from a linear relationship. In con-
trast, in females the increases were greater than the proportionate
dose increment, and at the highest nominal dose level the Cmax and
AUC0-24h values were ca 1.3-fold higher. The dose-adjusted Cmax of
the female rats to S6821 was generally slightly higher than that in
males. The dose-adjusted AUC0-24h of the female rats to S6821 was
generally similar to that in males at the two  lower dose levels (10
and 30 mg/kg bw/day), but was signiﬁcantly higher for the females
at the highest dose level (100 mg/kg bw/day). The dose-adjusted
AUC0-24h of the male and female rats to S6821 during Week 6 and
Week 13 was  similar to that on Day 7 and there was no statisti-
cally signiﬁcant evidence for any time (day of sampling) related
differences in systemic exposure.
There were no test article-related deaths during the study. Two
males and ﬁve females died or were sacriﬁced prematurely due to
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Table  4
Summary of in vivo toxicity studies conducted on S6821 and S7958.
Study Cmpd No. Species/Gender (N value) Dose Findings
28-Day Dose Range Finding Toxicity Study S6821 Male & Female
Sprague-Dawley Rats 5
animals/sex/group
10, 30, 100 mg/kg
bw/day (food ad-mix)
No test-article related ﬁndings;
MTD  > 100 mg/kg bw/day
90-Day  Sub-Chronic Toxicity Study S6821 Male & Female
Sprague-Dawley Rats 20
animals/sex/group
10, 30, 100 mg/kg
bw/day (food ad-mix)
No test-article related ﬁndings;
NOAEL = 100 mg/kg bw/day
28-Day Sub-Acute Toxicity Study S7958 Male & Female
Sprague-Dawley Rats 10
animals/sex/group
10, 30, 100 mg/kg
bw/day (food ad-mix)
No test-article related ﬁndings;
NOAEL = 100 mg/kg bw/day
Dose  Range Finding Developmental Toxicity Study S6821 Bred Female Sprague-Dawley
Rats 8 animals/group
125, 250, 500,
1000 mg/kg bw/day
(oral gavage)
No maternal toxicity or effect
on intrauterine growth up to
1000 mg/kg bw/day
Deﬁnitive Developmental Toxicity Study S6821 Bred Female Sprague-Dawley
Rats 25 animals/group
125, 300, 1000 mg/kg
bw/day (oral gavage)
NOAEL for both maternal
toxicity and embryo/fetal
development = 1000 mg/kg
bw/day
Table 5
Toxicokinetics of S6821 in male and female Sprague-Dawley rats (food ad-mix).
Time Point Dose (mg/kg bw) Sex Cmax (ng/mL) AUC0-24h (ng·h/mL) AUC0-24h/dose (ng·h/mL/mg/kg) Cmax Ratioa AUC0-24h Ratiob ACUM Ratioc
Day 7 10 M 6.05 118 11.8 1 1 –
F  7.22 122 12.2 1 1 –
30 M  16.7 295 9.83 2.8 2.5 –
F  27.7 436 14.5 3.8 3.5 –
100 M  41.4 844 8.44 6.8 7.2 –
F  99.0 1500 15.0 13.7 12.3 –
Week  6 10 M 10.7 126 12.6 1 1 1.07
F  6.34 113 11.3 1 1 0.93
30 M  24.6 293 9.77 2.3 2.3 0.99
F  17.5 331 11.0 2.8 2.9 0.76
100 M  43.7 758 7.58 4.1 6.0 0.90
F  95.6 1300 13.0 15.1 11.5 0.87
Week  13 10 M 5.99 123 12.3 1 1 1.04
F  8.32 125 12.5 1 1 1.02
30 M  18.3 305 10.2 3.1 2.5 1.03
F  19.8 344 11.5 2.4 2.8 0.79
100 M  54.7 925 9.25 9.1 7.5 1.10
F  107 1670 16.7 12.9 13.4 1.11
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na Cmax Ratio = Cmax/Cmax at 10 mg/kg bw dose.
b AUC0-24hr Ratio = AUC0-24hr/AUC0-24hr at 10 mg/kg bw dose.
c ACUM Ratio = AUC0-24hr at Week 6 or 13/AUC0-24hr at Day 7.
ccidental causes associated with routine blood sampling. Body-
eight gain and food consumption were unaffected by treatment
see Figs. 7 and 8). There were no test article-related clinical signs
bserved during the study and there were no treatment-related
phthalmic lesions. The appearance and behaviour of the animals,
ensory reactivity and grip strength were unaffected by treatment.
otor activity scores for males receiving 100 mg/kg bw/day were
lightly higher than those of controls (p < 0.05) and historical con-
rol scores during the second half of the 1-hour recording period,
ith scores for high beams and low beams (rearing and cage ﬂoor
ctivity, respectively) similarly increased. The pattern of activity
ndicated that males receiving 100 mg/kg bw/day failed to habit-
ate to the test cage environment to the same extent as control
ales. As there were otherwise no changes that were indicative
f an adverse effect of treatment, the increase in motor activity
as considered not adverse. Scores for females receiving 100 mg/kg
w/day and for males and females receiving 10 or 30 mg/kg bw/day
ere unaffected.
There were no test article-related effects among hematology
arameters, coagulation times, clinical chemistry analytes, or uri-
alysis parameters in either sex at any dose level. Any observeddifferences were minor and as the majority of individual values
were within the background range, were not considered toxi-
cologically signiﬁcant. There were no test article-related organ
weight, macroscopic or microscopic changes noted at any dose
level. All inter-group differences from controls were minor, seen
in one sex only and were therefore attributed to normal biolog-
ical variation. These included the slightly lower adjusted mean
liver weights in males (p < 0.05) and the slightly higher adjusted
mean spleen weights for females which received 100 mg/kg bw/day
(p < 0.05).
In conclusion, once daily oral administration of S6821 for
90 days was  well tolerated in rats at dose levels up to 100 mg/kg
bw/day, with the only effect occurring in the high dose males where
there was a slight increase of motor activity. No test article-related
mortality or evidence of any systemic toxicity was observed and no
target organs were identiﬁed. Based on the ﬁndings in this study
the no-observed-effect-level (NOEL) was considered to be 30 mg/kg
bw/day for males and 100 mg/kg bw/day for females and the no-
observed-adverse-effect level (NOAEL) was 100 mg/kg/day in both
sexes. See Supplementary Data for summary of the 90-day study
data for S6821.
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Fig. 7. Mean body weights of male Sprague-Dawley rats receiving S6821 for 13 weeks.
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Fig. 8. Mean body weights of female Spra
.1.3. 28-Day subacute toxicity study on S7958
The purpose of these studies was to evaluate the potential
oxicity of S7958 in rats after administration in diet for 28 con-
ecutive days. Three treatment groups of male and female CD®
Crl:CD®(SD)] rats (n = 10/sex/group, Charles River UK Ltd, Margate,
ent, England) were administered S7958 in the diet at dose levels
f 10, 30, or 100 mg/kg bw/day. One additional group of ten ani-
als/sex served as the control and received the vehicle diet. The test
ubstance was administered continuously via the diet throughout
he treatment period. Dietary concentrations were adjusted at the
ame frequency as bodyweight and food consumption measure-
ent to achieve constant doses in terms of mg/kg bw/day. At the
onclusion of the study, animals were sacriﬁced by carbon dioxide
sphyxiation before subsequent exsanguination.
Survival, clinical observations, body weight gain, food consump-
ion, hematology, clinical chemistry, urinalysis, organ weights,
acroscopic examination, and histopathologic evaluation were
erformed to assess potential toxicity. A sensory reactivity and
otor activity assessment (including, but not limited to, evalua-
ion of motor activity, arousal, auditory startle response, tail pinch
esponse, and grip strength) was conducted during the 4th week ofy Wee k
awley rats receiving S6821 for 13 weeks.
test article administration for all animals. Opthalmoscopic exami-
nations were conducted pre-dose and during the 4th week of test
article administration for animals in the control and high dose
groups. Samples for hematology, coagulation, and clinical chem-
istry evaluations were collected from all animals during Week 4.
Samples for urinalysis evaluations were collected from all ani-
mals during Week 4. Blood samples for proof of exposure were
obtained from the retro-orbital sinus on Day 29 at a single time
point (06:00 GMT) from ﬁve male and ﬁve female animals in
each dose group. Samples were also taken from the same animals
at necropsy from the hepatic portal vein. Microscopic examina-
tion of ﬁxed hematoxylin and eosin-stained parafﬁn sections were
performed on sections of tissues all animals in the control and
high-dose (100 mg/kg bw/day) groups.
Mean plasma concentrations of S7958 in samples obtained from
the peripheral blood at 06:00 h GMT  on Day 29, the mean plasma
concentrations of S7958 in samples obtained from the hepatic por-
tal vein at necropsy, and the relationship between the mean plasma
concentrations are summarised in Table 6.
The mean concentrations of S7958 in the peripheral blood on
Day 29 increased with increasing dose over the nominal range
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Table  6
Mean Concentrations of S7958 in the Peripheral and Portal Vein Blood.
Dose Sex Peripheral Blood Hepatic Portal Vein Blood
Mean Conc. (ng/mL) Mean Conc. Ratioa Mean Conc. (ng/mL) Mean Conc. Ratioa
10 mg/kg bw/day M 0.441 1 24.4 1
F  18.4 1 19.4 1
30  mg/kg bw/day M 1.79 4.1 68.2 2.8
F  66.7 3.6 85.0 4.4
M 18.3 41.5 345 14.1
.4 
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bw/day F  136 7
a Mean Concentration Ratio = mean concentration/mean concentration at 10 mg/
0–100 mg/kg bw/day but these increases were greater than the
roportionate dose increment in males and lower than the dose
ncrement in females. The mean concentrations of S7958 in the por-
al blood at necropsy also increased with increasing dose, however,
hese increases were greater than the proportionate dose incre-
ent in both males and females. Plasma concentrations of S7958
n the samples taken from the hepatic portal vein were generally
igher than those taken from the peripheral blood, which may
ndicate a marked ﬁrst-pass effect. These differences were partic-
larly marked in males. The plasma concentrations of S7958 in all
he samples taken from the control animals were below the limit
f quantiﬁcation (<0.500 ng/mL) demonstrating that there was no
uantiﬁable contamination in these animals.
There were no test article-related deaths during the study and
ll animals survived until scheduled euthanasia. There were no
phthalmic lesions in Week 4 that were considered to be asso-
iated with treatment. There were no test article-related clinical
igns observed during the study. The appearance, behaviour, sen-
ory reactivity ﬁndings, grip strength values and motor activity
cores of the animals were unaffected by treatment. Motor activity
cores for males and females showed some inter-group variation
ut the overall pattern of activity during the 1-hour recording
eriod showed no differences considered to be associated with
reatment.
Bodyweight gain was unaffected by treatment (see
igs. 9 and 10). The overall bodyweight gain of treated males
as slightly lower than that of the controls. There was  no dose
elationship and these small inter-group differences were not
onsidered associated with treatment. The overall bodyweight
ain of females receiving 100 mg/kg bw/day was  also slightly
ow when compared to the controls, however weekly gains were
ariable, particularly in Week 3 which accounted for the majority
f the difference from controls.
The hematological investigation in Week 4 did not identify any
oxicologically signiﬁcant ﬁndings. The biochemical examination
f the blood plasma in Week 4 revealed slightly low phosphorus
oncentrations in males and females receiving 10, 30 or 100 mg/kg
w/day, though statistical signiﬁcance was only achieved at 30 and
00 mg/kg bw/day (p < 0.05), and high chloride levels in females
eceiving 10, 30 or 100 mg/kg bw/day (p < 0.01). A number of other
nter-group differences from controls occurred but these tended to
e minor, conﬁned to one sex or lacked dosage-relationship and
ere therefore likely to represent normal biological variation. The
ppearance and composition of urine was not affected by treat-
ent.
There were no test article-related organ weight, macroscopic
r microscopic changes noted at any dose level of S7958. All
acroscopic and microscopic observations were considered inci-
ental/spontaneous, of the nature commonly observed in this strain
nd age of rats, and/or were of similar incidence and severity in
ontrol and treated animals.334 17.2
/day.
In conclusion, once daily oral administration of S7958 for
28 days was well tolerated in rats at dose levels up to 100 mg/kg
bw/day. No test article-related mortality or evidence of any sys-
temic toxicity was observed and no target organs were identiﬁed.
Based on these results, the NOAEL was considered to be 100 mg/kg
bw/day. See Supplementary Data for summary of the 28-day study
data for S7958.
6.2. Developmental toxicity studies
6.2.1. Dose range-ﬁnding developmental toxicity study
The objective of the study was  to determine dosage levels of
S6821 to be evaluated in a deﬁnitive developmental toxicity study
conducted in rats. The test article, S6821, in the vehicle (1% MC  [400
cps]) was administered orally by gavage to 4 groups of 8 bred female
Crl:CD(SD) rats (Charles River Laboratories, Raleigh, NC) once daily
from gestation days 6 through 20, at dosage levels of 125, 250, 500,
and 1000 mg/kg bw/day (dose volume 10 mL/kg). A concurrent con-
trol group composed of 8 bred females received the vehicle on a
comparable regimen. The females were approximately 12 weeks
of age when paired for breeding. Positive evidence of mating was
conﬁrmed by the presence of a vaginal copulatory plug or the pres-
ence of sperm in a vaginal lavage. The day on which evidence of
mating was identiﬁed was  termed gestation Day 0. All animals
were observed twice daily for mortality and moribundity. Clinical
observations, body weights, and food consumption were recorded
at appropriate intervals. On gestation Day 21, all animals were euth-
anized by carbon dioxide inhalation and a laparohysterectomy was
performed on each female. The uteri, placentae, and ovaries were
examined, and the numbers of fetuses, early and late resorptions,
total implantations, and corpora lutea were recorded. Gravid uter-
ine weights were recorded, and net body weights and net body
weight changes were calculated. The fetuses were weighed, their
sex determined, and examined for external malformations and
developmental variations.
All females survived to the scheduled necropsy on gestation Day
21; 2 females in the 1000 mg/kg bw/day dose group delivered on
this day (the expected day of delivery for this species). One female in
the 500 mg/kg bw/day group was determined to be nongravid. Clin-
ical ﬁndings noted at the daily examinations, including hair loss or
scabbing on various body surfaces, occurred infrequently, at similar
frequencies in the control group, and/or in a manner that was  not
dose-related. No test article-related clinical or macroscopic ﬁnd-
ings were noted at any dosage level. Mean maternal body weights,
body weight gains, net body weights, net body weight gains, gravid
uterine weights, and food consumption were unaffected by test
article administration up to 1000 mg/kg bw/day.
Intrauterine growth and survival were not affected by test article
administration at any dosage level. Parameters evaluated included
post-implantation loss, live litter size, mean fetal body weights, and
fetal sex ratios. Mean numbers of corpora lutea and implantation
sites and the mean litter proportions of pre-implantation loss were
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Fig. 9. Mean body weights of male Sprague-Dawley rats receiving S7958 for 4 weeks.
125
150
175
200
225
250
275
-7 -2 3 8 13 18 23 28
W
ei
gh
t (
g)
Stu
0 mg/kg/day
10 mg/kg/da y
30 mg/kg/da y
100 mg/kg/day
ague-
s
s
t
1
m
m
i
t
n
f
i
n
T
w
o
6
S
f
aFig. 10. Mean body weights of female Spr
imilar across all groups. Differences from the control group were
light and not statistically signiﬁcant. The numbers of fetuses (lit-
ers) available for morphological evaluation were 109(8), 114(8),
19(8), 101(7), and 118(8) in the control, 125, 250, 500, and 1000
g/kg bw/day groups, respectively. Cyclopia (proboscis-like nose,
icrostomia, and bilateral anophthalmia) was noted in one fetus
n the 250 mg/kg bw/day group. This ﬁnding was not considered
est article-related because it occurred in a single fetus and was
ot observed in the higher dosage groups. No other external mal-
ormations and no external developmental variations were noted
n fetuses in this study.
No evidence of maternal toxicity or embryo-fetal toxicity was
oted in this study at dosage levels up to 1000 mg/kg bw/day.
herefore, dosage levels of 125, 500, and 1000 mg/kg bw/day
ere selected for the deﬁnitive embryo/fetal development study
f S6821.
.2.2. Deﬁnitive developmental toxicity study
The objective of the study was to determine the potential of
6821 to induce developmental toxicity after maternal exposure
rom implantation to one day prior to expected parturition, to char-
cterize maternal toxicity at the exposure levels tested, and tody Day
Dawley rats receiving S7958 for 4 weeks.
determine a NOAEL for maternal and developmental toxicity. The
test article, S6821, in the vehicle (1% MC  [400 cps]) was  adminis-
tered orally by gavage to 3 groups of 25 bred female Crl:CD(SD)
rats (Charles River Laboratories, Kingston, NY) once daily from ges-
tation days 6 through 20, at dosage levels 125, 500, and 1000 mg/kg
bw/day (dose volume 10 mL/kg). A concurrent control group com-
posed of 25 bred females received the vehicle on a comparable
regimen. The females were approximately 13 weeks of age when
paired for breeding. Positive evidence of mating was conﬁrmed by
the presence of a vaginal copulatory plug or the presence of sperm
in a vaginal lavage. The day on which evidence of mating was iden-
tiﬁed was termed gestation Day 0. All animals were observed for
mortality, moribundity, clinical observations, body weights, and
food consumption. On gestation Day 21, all animals were eutha-
nized by carbon dioxide inhalation and a laparohysterectomy was
performed on each female. The uteri, placentae, and ovaries were
examined, and the numbers of fetuses, early and late resorptions,
total implantations, and corpora lutea were recorded. Gravid uter-
ine weights were recorded, and net body weights and net body
weight changes were calculated. The fetuses were weighed, their
sex determined, and examined for external, visceral, and skeletal
malformations and developmental variations.
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All females survived to the scheduled necropsy on gestation Day
1. Two females in the control group (0 mg/kg bw/day), and three
n the 1000 mg/kg bw/day dose group were determined to be non-
ravid. No signiﬁcant article-related clinical ﬁndings were noted at
he daily examinations or 1 h following dose administration at any
osage level.
Mean body weight, body weight gains and food consumption
ere comparable across all groups (See Fig. 11). Mean food con-
umption was signiﬁcantly (p < 0.01) higher on gestational Days
–9 in the 1000 mg/kg bw/day dosage group compared to the con-
rol; however, this was transient and did not affect the overall food
onsumption or body weight gain for the interval. Therefore, the
igher food consumption for this interval was not considered test
rticle-related. There were no signiﬁcant maternal necropsy ﬁnd-
ngs in any of the dose groups.
At the scheduled necropsy on gestation Day 21, no test arti-
le related internal ﬁndings were observed at any dosage levels.
acroscopic ﬁndings observed in the test article treated groups
ccurred infrequently, at similar frequencies in the control group,
nd/or in a manner that was not dose related.
Intrauterine growth and survival were unaffected by test article
dministration at any dosage level. Parameters evaluated included
ost-implantation loss, live litter size, mean fetal body weights,
nd fetal sex ratios. Mean numbers of corpora lutea and implan-
ation sites and the mean litter proportions of pre-implantation
oss were similar across all groups. There appeared to be a small,
hough dose-dependent, increase in early resorptions and post-
mplantation loss; however, the increase did not reach statistical
igniﬁcance and the high dose values were relatively similar to
hose reported in the historical control data (Table 7). A signif-
cantly (p < 0.01) higher mean female fetal weight was noted in
he 125 mg/kg bw/day group. The higher mean fetal weight in this
roup did not occur in a dose-dependent manner, and therefore
as not considered test article-related. Any other differences from
he control group were slight and/or did not occur in a dose-related
anner.
The numbers of fetuses (litters) available for morphological
valuation were 320(23), 347(25), 364(25), and 327(22) in the
ontrol, 125, 500, and 1000 mg/kg bw/day groups, respectively.
alformations were observed in 4(4), 3(2), 2(2), and 4(3) fetuses
litters) in these same respective dose groups and were considered
pontaneous in origin.
One fetus in the 1000 mg/kg bw/day group had localized fetal
dema (neck and thorax). One fetus in the control group and one in
he 500 mg/kg bw/day group had meningoencephalocele; both of
hese ﬁndings was conﬁrmed skeletally, consisting of misshapen
arietal and interparietal bones in the control group fetus and
isshapen frontal and nasal bones in the fetus in the 500 mg/kg
w/day group. One fetus in the 125 mg/kg bw/day group had uni-
ateral microphthalmia. These external malformations occurred
nfrequently in single fetuses, at similar frequencies in the concur-
ent control group, and/or in a manner that was not dose-related. In
ddition, the mean litter proportions of these ﬁndings were not sta-
istically signiﬁcantly different from the control group and/or were
ithin the ranges of values in the historical control data. Therefore,
hese ﬁndings were not attributed to test article administration.
External variations were limited to twinning, noted for two
etuses in the 125 mg/kg bw/day group; however, there was  only a
ingle occurrence of this ﬁnding and it did not occur in a dose-
elated manner. In addition, the mean litter proportion of this
nding was not statistically signiﬁcantly different from the con-
urrent control group. Therefore, this ﬁnding was not attributed to
est article administration.
The aforementioned fetus with localized edema in the
000 mg/kg bw/day group and one of the fetuses in the 125 mg/kg
w/day group had a total of 5 and 4 visceral malformations, Reports 3 (2016) 310–327 323
respectively. These visceral malformations included situs inversus
(trachea, esophagus, heart, great and major vessels, liver, stom-
ach, pancreas, spleen, kidneys, adrenals, and/or intestine laterally
transposed), lobular dysgenesis of the lungs (1 lobe present, bilat-
eral), small atrio-ventricular valve (bilateral), and interventricular
septal defect for both fetuses, and a malpositioned vena cava
(coursed between the right adrenal and kidney) for the fetus in the
1000 mg/kg bw/day group. In addition, the fetus in the 125 mg/kg
bw/day group had a small left ventricle (visceral developmental
variation). Lobular dysgensis of the lungs (1 lobe present, bilateral)
was also noted for one fetus in the concurrent control group, and
situs inversus (trachea, esophagus, heart, great and major vessels,
lungs, liver, stomach, pancreas, spleen, kidneys, adrenals, and/or
intestine laterally transposed) was  also noted for two fetuses from
the same litter in the concurrent control group. Two fetuses from
the same litter in the 1000 mg/kg bw/day group were noted with a
persistant truncus arteriosus which consisted of pulmonary arter-
ies that arose from the ascending aorta with an interventricular
septal defect. Right-sided aortic arch (aortic arch and descending
aorta coursed to the right of the vertebral column; right carotid
and right subclavian arteries arose independently from the aortic
arch [no brachiocephalic trunk]; left subclavian coursed retroe-
sophageal) was seen in the fetus in the 125 mg/kg bw/day group
noted above which had unilateral microphthalmia. These visceral
malformations occurred infrequently in single fetuses, at similar
frequencies in the concurrent control group, within single litters,
and/or in a manner that was not dose-related. In addition, the mean
litter proportions of these ﬁndings were not statistically signiﬁ-
cantly different from the control group and/or were within the
ranges of values in the historical control data. Therefore, these
ﬁndings were not attributed to test article administration.
Visceral developmental variations, including renal papilla(e)
not fully developed and/or distended ureter, small heart, hemor-
rhagic ring around the iris, accessory lobules of the liver, and pale
spleen, occurred infrequently, at similar frequencies in the concur-
rent control group, and/or in a manner that was not dose-related. In
addition, the mean litter proportions of these ﬁndings were not sta-
tistically signiﬁcantly different from the control group and/or were
within the ranges of values in the laboratories historical control
data. Therefore, these ﬁndings were not attributed to test article
administration.
There were no test article-related skeletal malformations noted
for fetuses at any dosage level. The fetus in the 1000 mg/kg bw/day
group noted above with persistent truncus arteriosus also had
sternoschisis (sternal bands not joined). Another fetus from a dif-
ferent litter in the 1000 mg/kg bw/day group had bent limb bones
(femur and humerus, bilateral). One fetus in the 500 mg/kg bw/day
group had fused sternebrae. Severely malaligned sternebrae were
noted for 2(2) fetuses (litters) in the 125 mg/kg bw/day group. Ver-
tebral anomaly with associated rib anomaly (absent, misshapen,
and fused arches and fused ribs) was also noted in one of these
fetuses. This is the same fetus described above that also had uni-
lateral microphthalmia and a right-sided aortic arch. A vertebra
anomaly (malpositioned and missized arches) was also noted for
one fetus in the concurrent control group. These skeletal malforma-
tions occurred infrequently in single fetuses, at similar frequencies
in the concurrent control group, and/or in a manner that was  not
dose-related. In addition, the mean litter proportions of these ﬁnd-
ings were not statistically signiﬁcantly different from the control
group and/or were within the ranges of values in the historical con-
trol data. Therefore, these ﬁndings were not attributed to test article
administration.Skeletal variations observed in the test article-treated groups
occurred infrequently, at similar frequencies in the concurrent
control group, and/or in a manner that was  not dose related. A
slight increase in 27 presacral rib(s) was noted in the 1000 mg/kg
324 D.S. Karanewsky et al. / Toxicology Reports 3 (2016) 310–327
225
250
275
300
325
350
375
400
425
450
0 3 6 9 12 15 18 21
0 mg/kg/day
125 mg/kg/da y
500 mg/kg/da y
1000  mg/kg/day
M
at
er
na
l B
od
y 
W
ei
gh
t (
g)
Gestation al  Day 
Fig. 11. Oral (Gavage) Developmental Toxicity Study of S6821 in Rats: Mean maternal body weights during gestation (0 mg/kg bw/d: n = 23; 125, and 500 mg/kg bw/d:
n  = 25/group; 1000 mg/kg bw/d: n = 22/group).
Table 7
Developmental Toxicity Study of S6821 in Rats: Summary of Fetal Data.
Dose Group
(mg/kg
bw/day)
Fetuses Sex Viable
Fetuses
Dead
Fetuses
Resorptions Post-
Implant.
Loss
Implant.
Sites
Corpora
Lutea
Pre-
Implant.
Loss
Fetal Wt.
(g)
No. of
Gravid
Females
M F Early Late
0 Total 165 155 320 0 9 0 9 329 388 59 NA 23
Mean 7.2 6.7 13.9 0.0 0.4 0.0 0.4 14.4 16.9 2.6 5.5
S.D.  2.37 3.32 3.87 0.00 0.72 0.00 0.72 3.77 3.88 6.04 0.43
S.E.  0.49 0.69 0.81 0.00 0.15 0.00 0.15 0.79 0.81 1.26 0.09
125 Total  177 170 347 0 17 0 17 364 484 20 NA 25
Mean 7.1 6.8 13.9 0.0 0.7 0.0 0.7 14.6 15.4 0.8 5.7
S.D.  2.02 1.50 1.86 0.00 0.75 0.00 0.75 1.87 2.10 0.96 0.25
S.E.  0.40 0.30 0.37 0.00 0.15 0.00 0.15 0.37 0.42 0.19 0.05
500 Total  179 185 364 0 19 1 20 384 415 31 NA 25
Mean 7.2 7.4 14.6 0.0 0.8 0.0 0.8 15.4 16.6 1.2 5.6
S.D.  1.65 1.80 1.89 0.00 0.88 0.20 0.91 1.70 2.24 1.42 0.24
S.E.  0.33 0.36 0.38 0.00 0.18 0.04 0.18 0.34 0.45 0.28 0.05
1000 Total  165 162 327 0 20 0 20 347 372 25 NA 22
Mean 7.5 7.4 14.9 0.0 0.9 0.0 0.9 15.8 16.9 1.1 5.6
S.D.  2.13 2.74 2.64 0.00 1.54 0.00 1.54 2.05 1.90 1.28 0.33
0.00
N
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aS.E.  0.46 0.56 0.56 0.00 0.33 
A = not applicable.
w/day group compared to the control group (8 from 2 litters in
he 1000 mg/kg bw/day group compared to 1 from 1 litter in the
ontrol group). This increase was primarily due to a single litter
hat consisted of 7 fetuses with 27 presacral rib(s) in association
ith a 14th rudimentary rib. Due to the majority of this variation
temming from a single litter, and that this ﬁnding did not reach sta-
istical signiﬁcance, the higher incidence of 27 presacral rib(s) is not
onsidered test article-related. In addition, the mean litter propor-
ions of these ﬁndings were not statistically signiﬁcantly different
rom the control group and/or were within the ranges of values
n the historical control data. Therefore, these ﬁndings were not
ttributed to test article administration.
Based on the lack of adverse maternal toxicity or effects on
ntrauterine growth and survival and fetal morphology at any
osage level, a dosage level of 1000 mg/kg bw/day (the high-
st dosage level evaluated) was considered to be the NOAEL for
aternal toxicity and embryo/fetal development when S6821 was
dministered orally by gavage to bred Crl:CD(SD) rats. 0.33 0.44 0.41 0.27 0.07
7. Discussion
S6821 and S7958 are members of a novel series of antagonists
of the human bitter receptor hTAS2R8 which have demonstrated
the ability to signiﬁcantly attenuate the bitter taste of a variety
of bitter tastants present in consumer products including caffeine,
rebaudioside A, whey protein and hydrolyzed soy protein. In CYP
inhibition assays using both spectroﬂuorimetric substrates with
recombinant enzymes and CYP-speciﬁc substrates with pooled
human liver microsomes, S7958 exhibited signiﬁcant inhibition
of CYP2C9 (IC50 = 8.8 M,  using pooled human liver microsomes).
However, given the low use levels of S7958 and its low systemic
bioavailability after oral administration, this is not expected to
interfere with normal metabolic processes. In contrast, S6821 did
not signiﬁcantly inhibit any of the CYP isozymes in either assay for-
mat. No other signiﬁcant off-target activities were seen with either
S6821 or S7958 in any of the receptor proﬁling assays.
Based on in vitro studies with rat and human liver microsomes,
S6821 is metabolized by CYP oxidative enzymes to produce several
mono-hydroxylated metabolites. Subsequent in vivo metabolism
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tudies in the rat indicated that the major metabolic pathway for
limination of S6821 involved reaction of the phenolic moiety of
6821 with Phase II enzymes to produce the corresponding sul-
ate (M461) and glucuronide (M557) conjugates. In vivo, the rat
roduces all of the mono-hydroxylated metabolites seen in the
uman microsomal incubations along with the conjugated forms
e.g., sulfate, glucuronide) of the parent compound and its mono-
ydroxylated metabolites. Taken together, these ﬁndings support
he rat is a suitable species for assessing the potential toxicity of
6821. Similarly, in the case of S7958, ions consistent with the
resence of S7958 glucuronide and sulfate metabolites as well
s a sulfate derivative of a mono-hydroxylated metabolite were
bserved in the extracted ion chromatograms of the plasma sam-
les. Although plasma concentrations of the parent compound
7958 are signiﬁcantly less than those seen with S6821, S7958
emonstrates an overall metabolism proﬁle similar to that of its
lose analogue S6821.
Following intravenous administration of S6821 to male SD rats
limination of both the parent and the glucuronide metabolite
557 was found to be rapid (t1/2 of 0.1 and 0.2 h respectively), while
limination of the sulfate metabolite M461 was signiﬁcantly slower
t1/2 = 1.9 h), indicating that the rate of formation of the metabolite
as not the rate-limiting step in its elimination. Systemic exposure
AUClast) was shown to be highest for metabolite M461 while the
xposure to S6821 and metabolite M557 were similar. The total
lasma clearance of S6821 was higher than the reported hepatic
lood ﬂow in rats and the volume of distribution at steady state
as less than the reported total body water in rats.
Following oral administration of S6821 to male SD rats, S6821
bsorption was rapid with a terminal t1/2 of 4.3 h (at the highest
ose level). The terminal t1/2 of metabolites M461 and M557 ranged
etween 2.5–4.7 and 1.4–4.2 h respectively, with the longest t1/2
eing exhibited at the highest dosage. The rate (Cmax) and extent
AUClast) of systemic exposure to the parent and metabolites was
hown to increase with increasing dosage, but tended not to be
roportional to dose as predicted from a linear relationship. Most
igniﬁcantly, the systemic exposure of metabolites M461 and M557
anged from 160- to 650- and from 109- to 216-fold higher than
hat of S6821, respectively. Given the signiﬁcantly lower systemic
xposure of S6821 relative to metabolites M461 and M557, any in
ivo ﬁndings in the rodent toxicology studies might more likely be
ttributed to these metabolites rather the parent compound S6821.
S6821 was evaluated for its genotoxic potential through a
tandard battery of in vitro genotoxicity assays which included
 bacterial reverse mutation assay (S. typhimurium strains TA98,
A100, TA1535, TA1537 and E. coli strain WP2  uvrA), and a chro-
osome aberration test in HPBL. S6821 was found to be neither
utagenic or clastogenic in these in vitro genotoxicity assays. Its
lose analog S7958, also showed no evidence of mutagenicity in the
acterial reverse mutation assays either in the presence or absence
f metabolic activation.
S6821 also evaluated in an in vivo mouse micronucleus assay.
ral administration of S6821 at doses of 500, 1000, and 2000 mg/kg
w to male and female CD-1 mice for two consecutive days were
ell tolerated and did not induce clastogenicity nor indicate inter-
ctions with the mitotic spindle in bone marrow erythrocytes. No
ppreciable reductions in the PCE/TE ratio in the test article group
ompared to the vehicle control group were observed indicating
he S6821 also did not induce cytotoxicity. No signiﬁcant changes
n body weight or apparent signs of toxicity were observed in mice
dministered S6821 during the study period.
The doses of S6821 and S7958 selected for the 28- and 90-day
oxicology studies were designed to provide a high margin of safety
ather than deﬁne a maximum tolerated dose (MTD) in rats. Apply-
ng a margin of safety of 1000-fold in extrapolating animal data to
umans to account for species differences in susceptibility, numer- Reports 3 (2016) 310–327 325
ical differences in population ranges between the test animals and
the human population, the greater variety of complicating disease
processes in the human population, and the possibility of syner-
gistic action among food additives, is believed to be an adequate
margin of safety for most substances proposed for use in food [32];
[12].
The Joint FAO/WHO Expert Committee on Food Additives
(JECFA) employed both the maximized survey-derived intake
(MSDI) method and single portion exposure technique (SPET) as
measures of dietary exposure to ﬂavouring agents for use in their
safety evaluation of these compounds [21]. The MSDI is based on the
reported amount of a ﬂavouring agent introduced into the food sup-
ply per year in speciﬁc regions of the world and provides a per capita
estimate of the exposure to the ﬂavouring agent, assuming that 10%
of the relevant population would consume foods containing the
ﬂavouring agent. However, in many cases the MSDI is believed to
underestimate the dietary exposure to some ﬂavouring agents. The
SPET was developed to account for speciﬁc consumer patterns of
behaviour with respect to food consumption and possible uneven
distribution of dietary exposure for consumers of foods containing
ﬂavouring agents [21]. The SPET provides an estimate of the dietary
exposure for an individual who consumes a speciﬁc food product
containing the ﬂavouring agent every day and combines an aver-
age added use level with the standard portion size for a particular
food category. The dietary exposure from the single food category
leading to the highest dietary exposure from one portion is taken
as the SPET estimate. Based on the SPET value obtained from non-
alcoholic beverages, JECFA estimated the dietary exposure of both
S6821 and S7958 (JECFA Nos. 2161 and 2162) to be 4000 g/day
or 67 g/kg bw/day [22]. Therefore, based on this calculation, a
NOAEL of 100 mg/kg bw/day in the 28- and 90-day toxicology stud-
ies would be 1500 times the estimated dietary exposure to either
S6821 or S7958 when used as a ﬂavouring agent.
Dietary administration of S6821 rats for either 28 or 90 days
at doses of up to 100 mg/kg bw/day was generally well tolerated.
There was no effect of treatment on clinical signs, bodyweight,
food consumption, ophthalmic function, hematological param-
eters, blood chemistry parameters, urine, macropathology or
histopathology.
The TK investigations in the 90-day study indicated that the
rate and extent of systemic exposure of rats to S6821 was char-
acterised by nonlinear (dose-dependent) kinetics over the nominal
dose range 10–100 mg/kg bw/day. Increasing the dose above 30
mg/kg bw/day resulted in a lower systemic exposure in males, but
a higher systemic exposure in females, than would be predicted
from a linear relationship. In general, there were no differences
in the systemic exposure of male and female rats to S6821 at the
lower doses of 10 or 30 mg/kg bw/day. However, at the highest
dose (100 mg/kg bw/day) the systemic exposure of females was
signiﬁcantly higher than that of males. There were no time-related
differences in systemic exposure in either sex. The less than dose-
proportional increase in exposure in males suggests that the higher
doses of S6821 may  be inducing the further metabolism of S6821
on repeat dosing in males, but not in female rats. This is further
supported by the observation that in the single dose PK study in
male rats, exposure (AUC) at the 100 mg/kg bw/day dose was  some-
what greater than dose proportional. In female rats, the greater
than dose-proportional exposure at 100 mg/kg bw/day may be due
to saturation of a clearance pathway. In vivo metabolism studies in
rats have shown that S6821 is not only rapidly metabolized to the
corresponding sulfate M461 and glucuronide M557 conjugates, but
can also be hydroxylated and subsequently sulfated. Therefore, it is
possible that these metabolic pathways are further induced at high
doses in males, but become saturated in females at the same dose.
Gender-dependent metabolism of xenobiotics and sexual dimor-
phisms in response to inducing agents are well known phenomena
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n rats that has been attributed to differences in the proﬁle of CYP
sozymes found in male and female rat liver [24,38].
In the 90-day toxicity study of S6821, motor activity (both high
nd low beam scores; observation period of 60 min) was slightly
ncreased for males receiving 100 mg/kg bw/day when compared
o that of controls (p < 0.05) and historical control data. Females
eceiving 100 mg/kg bw/day were unaffected (see motor activity
cores in the Supplemental Material for details). As noted above,
he TK study indicated that the exposure to S6821 was signiﬁcantly
ower in males than females at 100 mg/kg bw/day dose and there-
ore the increased motor activity in males may  be more likely due
o higher levels of a S6821 metabolite. The pattern of ﬁndings at
he motor activity assessment indicated that the high dose males
ailed to habituate to the test cage environment to the same extent
s control males. No increase in activity was noted during clini-
al signs recorded throughout the treatment period. As there were
therwise no changes that were indicative of an adverse effect
f treatment, the increase in motor activity was  not considered
dverse. Based on the ﬁndings in this study the NOEL for S6821
as considered to be 30 mg/kg bw/day for males and 100 mg/kg
w/day for females, and the NOAEL was 100 mg/kg bw/day in both
exes.
Dietary administration of S7958 rats for 4 weeks at doses of up to
00 mg/kg bw/day was also generally well tolerated. There was  no
ffect of treatment on clinical signs, behavioural tests, bodyweight,
ood consumption, ophthalmic function, hematological parame-
ers, urine, macropathology or histopathology demonstrating that
he test substance was of low toxicity.
The mean concentrations of S7958 in the peripheral and por-
al vein blood increased with increasing dose over the dose range.
hese increases were greater than the proportionate dose incre-
ent in the peripheral blood of males and in the portal vein blood
f both males and females. In contrast, the increase in the mean
oncentrations of S7958 in the peripheral blood of the females was
ower than the dose increment. Plasma concentrations of S7958
n the samples taken from the hepatic portal vein were generally
igher than those taken from the peripheral blood, which may  indi-
ate a marked ﬁrst-pass effect. These differences were particularly
arked in males.
Minor electrolyte changes were noted for all treated groups but
s there was no histopathological correlate in the kidneys, these
hanges were not considered to be adverse. Based on the ﬁndings
n this study the NOAEL for S7958 was 100 mg/kg bw/day in both
exes.
In the developmental toxicity study of S6821, there were no
est article-related clinical or macroscopic ﬁndings were noted
t any dosage level. Mean maternal body weights, body weight
ains, gravid uterine weights, and food consumption were unaf-
ected by test article administration at all dosage levels. No test
rticle-related ﬁndings were noted on intrauterine growth and sur-
ival and fetal morphology at any dosage level. When the total
alformations and developmental variations were evaluated on
 proportional basis, no statistically signiﬁcant differences from
he control group were noted. Fetal malformations and develop-
ental variations, when observed in the test article treated groups,
ccurred infrequently or at a frequency similar to that in the con-
rol group, did not occur in a dose-related manner, and/or were
ithin the laboratories historical control data ranges. Based on
hese data, no fetal malformations or developmental variations
ere attributed to the test article at any dosage level.
Based on the lack of maternal toxicity or effects on intrauterine
rowth and survival and fetal morphology at any dosage level, a
osage level of 1000 mg/kg bw/day (the highest dosage level eval-
ated) was considered to be the NOAEL for S6821 for both maternal
oxicity and embryo/fetal development.
[
[ Reports 3 (2016) 310–327
8. Conclusions
S6821 demonstrated a lack of genotoxicity with or without
metabolic activation in vitro at concentrations that greatly exceed
those observed in rat plasma following oral administration of
S6821 at doses up 100 mg/kg bw.  The corresponding 5,5-dimethyl
analog S7958 also demonstrated a lack of mutagenicity in a reverse
bacterial mutation assay. S6821 had a NOAEL of 1000 mg/kg bw/day
for both maternal toxicity and embryo/fetal development in rats.
The results of a 90-day subchronic toxicity study with S6821 and
a 28-day short term toxicity study with S7958 established NOAELs
for both compounds of 100 mg/kg bw/day (the highest dose eval-
uated), for both male and female rats. Assuming that the systemic
exposure of these compounds after oral administration to humans
is comparable to that observed at an equivalent dose in the rat,
these NOAELs are orders of magnitude higher than the expected
human exposure for both compounds under the conditions of
intended use.
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